Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 53, Issue 2, 2012, Pages 225-234

  Hornberger, John ^a,b   Reyes, Carolina ^c,d   Shewade, Ashwini ^a   Lerner, Susan ^e   Friedmann, Mark ^a   Han, Leona ^a   Gutierrez, Hialy ^a   Satram Hoang, Sacha ^c   Keating, Michael J ^e  

^a Cedar Associates LLC   (United States)

^b STANFORD UNIVERSITY   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia; Cost effectiveness; Cyclophosphamide; Fludarabine; Previously untreated; Rituximab

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADULT; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH STATUS; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SALVAGE THERAPY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE; VIDARABINE;

EID: 84856080627     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.605918     Document Type: Article

References (43)

1. Hernandez A, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995;75:381-94.
2. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Chronic lymphocytic leukemia [Internet]. April 2011. Available from: http://seer.cancer.gov/statfacts/html/clyl.html
3. Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 2008;111:4916-4921.
4. Hartmann T, Pleyer L, Desch P, et al. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights. Discov Med 2009;8:157-164.
5. Maddocks K, Lin T. Update in the management of chronic lymphocytic leukemia. J Hematol Oncol 2009;2:29.
6. Pleyer L, Egle A, Hartmann T, et al. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009;6:405-418.
7. Rai K, Keating M. Initial treatment of chronic lymphocytic leukemia. In: Basow DS, editor. UpToDate. Waltham, MA: UpToDate; 2009.
8. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
9. Greenberg D, Earle C, Fang CH, et al. When is cancer care costeffectsive? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010;102:82-88.
10. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27:3868-3874.
11. Stram M, Taberkiewicz J, Hus I, et al. New approaches in treatment of B-cell chronic lymphocytic leukemia. Cancer Ther 2009;7:163-173.
12. Weinstein MC. Recent developments in decision-analytic modeling for economic evaluation. Pharmacoeconomics 2006;24:1043-1053. (Pubitemid 44683362)
13. Tam C, O'Brien S, Wierda W, et al. Long-term results of the fl udarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-980.
14. Arias E. National Vital Statistics Report [Internet]. November 2010. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58-21.pdf
15. Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:227-236. (Pubitemid 351200289)
16. Centers for Medicare & Medicaid Services Physician Fee Schedule [Internet]. Baltimore, MD: CMS; June 2009. Available from: http://www.cms.gov/
17. Byrd J, Murphy T, Howard R, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-2164. (Pubitemid 32366969)
18. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fl udarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-2053.
19. Dungarwalla M, Evans S, Riley U, et al. High dose methylprednisolone and rituximab is an effectsive therapy in advanced refractory chronic lymphocytic leukemia resistant to fl udarabine therapy. Haematologica 2008;93:475-476. (Pubitemid 351398657)
20. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fl udarabine and cyclophosphamide prolongs progression-free survival compared with fl udarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-1765.
21. Robak T, Smolewski P, Cebula B, et al. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007;79:107-113. (Pubitemid 47063264)
22. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224. (Pubitemid 29467667)
23. Woyach J, Lin T, Lucas M, et al. A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009;23:912-918.
24. Hassett MJ. The full burden of cancer. Oncologist 2010;15: 793-795.
25. Van Houtven CH, Ramsey SD, Hornbrook MC, et al. Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist 2010;15:883-893.
26. Szafran R. Age-adjusted labor force participation rates, 1960- 2045 [Internet]. 2002. Available from: http://www.bls.gov/opub/mlr/2002/09/art3full. pdf
27. May 2009 National occupational employment and wage estimates, United States. Bureau of Labor Statistics [Internet]. 2009. Available from: http://www.bls.gov/oes/current/oes-nat.htm#00-0000
28. O verview of BLS statistics on infl ation and prices [Internet]. 2010. Available from: http://www.bls.gov/bls/infl ation.htm
29. Weinstein MC, O 'B rien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6:9-17. (Pubitemid 36228345)
30. Lipscomb J, Weinstein M, Torrance G. Time preference. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectsiveness in health and medicine. New York: Oxford University Press; 1996. pp. 214-246.
31. Beusterien KM, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 2010;8:50.
32. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectsiveness analysis. J HealThecon 2005;24:751-773. (Pubitemid 40800157)
33. Basu A, Dale W, Elstein A, et al. A time tradeoff method for eliciting partner ' s quality of life due to patient ' s health states in prostate cancer. Med Decis Making 2010;30:355-365.
34. Bennett CL, Golub R, Waters TM, et al. Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997;15:227-236. (Pubitemid 27261663)
35. Bennett CL, Waters TM. Economic analyses in clinical trials for cooperative groups: operational considerations. Cancer Invest 1997;15:448-453. (Pubitemid 27439231)
36. Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectsiveness analysis alongside clinical trials: the ISPOR RCTCEA Task Force report. Value Health 2005 8:521-533. (Pubitemid 41727304)
37. Amend KL, Turnbull B, Foskett N, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010;75:1326-1332.
38. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-4840.
39. Carson KR, Focosi D, Major EO, et al. Monoclonal antibodyassociated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10:816-824.
40. D' Souza A, Wilson J, Mukherjee S, et al. Progressive multifocal leukoencephalopathy in chronic lyhmphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010;10:E1-E9.
41. Carr E, Lerner S, Aultman R, et al. Treatment effects of fi rst line rituximab, fl udarabine and cyclosphosphamide in a chronic lymphocytic leukemia patient cohort: an evaluation of prognostic factors, estimated life expectancy and economic outcomes. Blood 2008;112(Suppl. 1): Abstract 2396.
42. Rituximab for the fi rst-line treatment of chronic lymphocytic leukaemia. National Institute for Health and Clinical Excellence [Internet]. November 2009. Available from: http://www.nice.org.uk/nicemedia/live/11907/44906/44906. pdf
43. F ludarabine, cyclophosphamide, and rituximab or bendamustine and rituximab in treating patients with previously untreated B-cell chronic lymphocytic leukemia [Internet]. February 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00769522/